Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is devastating. Because of its silent nature, the disease is often only diagnosed once it has reached an advanced, frequently inoperable stage. To date, we have no biomarkers that facilitate earlier diagnosis, leaving sufficient time for curative therapy that effectively lowers the very high mortality rate of this cancer entity. Because of this, the life expectancy of patients with PDAC is low (i.e. ≤ 6% five-year survival rates). New data, including particular genetic signatures and features of the stromal architecture of PDAC tumors, may better explain their aggressiveness, their relatively long-lasting painless expansion, and why chemotherapy so frequently fails. The typical tumor-induced stromal desmoplasia is characterized by cancer-associated fibroblasts (CAFs), decreased immune surveillance, cancer-associated neural remodeling, and a very low vascular density. This stromal microenvironment generates hypoxia, nutrient deficiency, immune suppression, and chemoresistance. The combination of factors results in a vicious disease that begins with the long-lasting, asymptomatic development of a large tumor mass, followed by a delayed diagnosis with a high percentage of inoperable states, exhibiting a poor response to all conservative therapeutic options, including radiation, and which ends with metastasis resulting in a rapid fatal outcome.
Objective: In this article, we review coherences on genetic, cellular, immunological, Nano medical and stromal characteristics of PDAC tissue, and discuss metabolic abnormalities associated with and/or preceding the tumor progression rate.
Conclusion: A more comprehensive understanding of the underlying mechanisms can improve the diagnostic and therapeutic management of patients suffering from this devastating type of cancer.
Keywords: Pancreatic ductal adenocarcinoma, new insights in stroma pdac cell interactions, neural remodelling aspects, immunological aspects, metabolic aspects, genetic aspects, nanomedical aspects.
Current Medicinal Chemistry
Title:New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma
Volume: 24 Issue: 28
Author(s): Harald Mangge *, Tobias Niedrist, Wilfried Renner , Stefan Lyer , Christoph Alexiou and Johannes Haybaeck
Affiliation:
- Clinical Institute of Medical and Chemical Laboratory Diagnosis, Medical University of Graz, Auenbruggerplatz 30, 8036 Graz,Austria
Keywords: Pancreatic ductal adenocarcinoma, new insights in stroma pdac cell interactions, neural remodelling aspects, immunological aspects, metabolic aspects, genetic aspects, nanomedical aspects.
Abstract: Background: Pancreatic ductal adenocarcinoma (PDAC) is devastating. Because of its silent nature, the disease is often only diagnosed once it has reached an advanced, frequently inoperable stage. To date, we have no biomarkers that facilitate earlier diagnosis, leaving sufficient time for curative therapy that effectively lowers the very high mortality rate of this cancer entity. Because of this, the life expectancy of patients with PDAC is low (i.e. ≤ 6% five-year survival rates). New data, including particular genetic signatures and features of the stromal architecture of PDAC tumors, may better explain their aggressiveness, their relatively long-lasting painless expansion, and why chemotherapy so frequently fails. The typical tumor-induced stromal desmoplasia is characterized by cancer-associated fibroblasts (CAFs), decreased immune surveillance, cancer-associated neural remodeling, and a very low vascular density. This stromal microenvironment generates hypoxia, nutrient deficiency, immune suppression, and chemoresistance. The combination of factors results in a vicious disease that begins with the long-lasting, asymptomatic development of a large tumor mass, followed by a delayed diagnosis with a high percentage of inoperable states, exhibiting a poor response to all conservative therapeutic options, including radiation, and which ends with metastasis resulting in a rapid fatal outcome.
Objective: In this article, we review coherences on genetic, cellular, immunological, Nano medical and stromal characteristics of PDAC tissue, and discuss metabolic abnormalities associated with and/or preceding the tumor progression rate.
Conclusion: A more comprehensive understanding of the underlying mechanisms can improve the diagnostic and therapeutic management of patients suffering from this devastating type of cancer.
Export Options
About this article
Cite this article as:
Mangge Harald*, Niedrist Tobias , Renner Wilfried, Lyer Stefan , Alexiou Christoph and Haybaeck Johannes , New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma, Current Medicinal Chemistry 2017; 24 (28) . https://dx.doi.org/10.2174/0929867324666170510150124
DOI https://dx.doi.org/10.2174/0929867324666170510150124 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology The Utilization of Gene Targeting Models During in Preclinical Study of Drug Discovery Process - Example of Phenotypic and Functional Analysis of Cacna1 βGene Product
Current Pharmaceutical Biotechnology Obesity and Insulin Resistance: Associations with Chronic Inflammation, Genetic and Epigenetic Factors
Current Medicinal Chemistry Meet the Editor in Chief:
Current Organocatalysis Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Applications of Ultrasound Elastography in Musculoskeletal Imaging: Technical Aspects and Review of the Literature
Current Medical Imaging Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology PDGF-D Signaling: A Novel Target in Cancer Therapy
Current Drug Targets Transplantation of Pancreatic Islets Immobilized in Alginate-Based Microcapsules: From Animal Studies to Clinical Trials
Micro and Nanosystems Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Dysregulation of Lysyl Oxidases Expression in Diabetic Nephropathy and Renal Cell Carcinoma
Current Drug Targets Living without Oxygen: Anoxia-Responsive Gene Expression and Regulation
Current Genomics Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia
Current Pharmaceutical Biotechnology Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design Cortex Lycii Radicis Extracts Protect Pancreatic Beta Cells Under High Glucose Conditions
Current Molecular Medicine Pregnancy Complicated by the Most Frequent Forms of Maturity Onset Diabetes of the Young: A Narrative Review on Its Pharmacological Implications
Current Reviews in Clinical and Experimental Pharmacology Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design Bioactive Compounds Effective Against Type 2 Diabetes Mellitus: A Systematic Review
Current Topics in Medicinal Chemistry